Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
Significantly more patients had histologic response with benralizumab than placebo, but no significant difference seen in dysphagia symptoms
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.